Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

A team of international researchers including those from the University of Adelaide have taken a well-known chemical reaction ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.38 per share for the third quarter of 2024, ...

“You should also have an ophthalmologist to refer to when you have a patient with thyroid eye disease that needs urgent ...

Company Continues to Pursue Review of Strategic AlternativesWOBURN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine ...

Report on how AI is redefining market landscape - The global gastroparesis drugs market  size is estimated to grow by USD 1.42 billion from 2024-2028, according to Technavio. The market is estimated ...

Good day and welcome to the Vertex Pharmaceuticals third-quarter 2024 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to ...

Q3 2024 Earnings Call Transcript November 4, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.38, expectations were $4.14. Operator: Good day. And welcome to ...